{
    "clinical_study": {
        "@rank": "127725", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1: IPI-145 plus Rituximab", 
                "arm_group_type": "Experimental", 
                "description": "IPI-145 will be administered orally, twice daily, in 28-day cycles.  The starting dose will be 50 mg twice-daily (BID).  A maximum of 12 cycles of IPI-145 will be administered.\nRituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly during a 28 day cycle; 2 cycles of rituximab will be administered."
            }, 
            {
                "arm_group_label": "Arm 2: IPI-145 plus Rituximab and Bendamustine", 
                "arm_group_type": "Experimental", 
                "description": "IPI-145 will be administered orally, twice daily, in 28 day cycles.  The starting dose will be 50 mg twice-daily (BID).  A maximum of 12 cycles of IPI-145 will be administered.\nRituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly of each 28 day cycle. A maximum of 6 cycles of rituximab will be given.\nBendamustine 90 mg/m2 will be administered IV on Days 1 and 2 of each 28 day cycle.  A maximum of 6 cycles of bendamustine will be given."
            }, 
            {
                "arm_group_label": "Arm 3: IPI-145 plus Bendamustine", 
                "arm_group_type": "Experimental", 
                "description": "IPI-145 will be administered orally, twice daily, in 28 day cycles.  The starting dose will be 50 mg twice-daily (BID).  A maximum of 12 cycles of IPI-145 will be administered.\nBendamustine 120 mg/m2 will be administered IV on Days 1 and 2 of each 28 day cycle.  A maximum of 6 cycles of bendamustine will be given."
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of this study is to characterize the safety, maximum tolerated dose (MTD) and\n      preliminary efficacy profile of IPI-145 given in combination with rituximab, bendamustine\n      plus rituximab or bendamustine to subjects with select relapsed/refractory hematologic\n      malignancies."
        }, 
        "brief_title": "Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lymphoma", 
            "Chronic Lymphocytic Leukemia", 
            "Non-Hodgkin Lymphoma", 
            "T-cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, T-Cell", 
                "Hematologic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This trial consists of three parallel arms.  For each treatment arm, a 3+3 dose escalation\n      design will be applied in 3-6 subject cohorts until the maximum tolerated dose of IPI-145\n      when given with rituximab (Arm 1), or in combination with rituximab and bendamustine (Arm 2)\n      or with bendamustine (Arm 3) is determined.  The population during dose escalation will be\n      limited to subjects diagnosed with NHL with at least one prior anticancer treatment.  Once\n      the MTD of each arm has been determined, the arms will move on to a dose expansion phase.\n      During the dose expansion phase, each treatment arm will enroll to population specific\n      cohorts.  All subjects must have had at least one prior anticancer treatment.  The dose\n      expansion cohorts are:\n\n      Arm 1:   Cohort A - CLL,   Cohort B - CD20+ NHL; Arm 2:   Cohort A - CLL,   Cohort B - CD20+\n      NHL; Arm 3:   Cohort C - T-Cell Lymphoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Dose Escalation Phase Arm 1 and Arm 2: Limited to subjects diagnosed with low grade\n             CD-20 positive B-Cell NHL with at least one prior anticancer treatment.\n\n             Arm 3: Limited to subjects with a diagnosis of NHL with at least one prior anticancer\n             treatment.\n\n          2. Dose Expansion Phase Arm 1  Cohort A: Limited to subjects with CD-20 positive CLL\n             with at least one prior anticancer treatment.\n\n             Arm 1  Cohort B: Limited to subjects with diagnosis of CD-20 positive NHL with at\n             least one prior anticancer treatment.\n\n             Arm 2 Cohort A: Limited to subjects with   CD-20 positive CLL with at least one prior\n             anticancer treatment.\n\n             Arm 2  Cohort B: Limited to subjects with diagnosis of CD-20 positive NHL with at\n             least one prior anticancer treatment.\n\n             Arm 3  Cohort C:  Limited to subjects with T-cell lymphoma who have had at least one\n             prior anticancer treatment.\n\n          3. Disease status requirement:\n\n               -  CLL subjects: symptomatic disease that mandate treatment;\n\n               -  Indolent NHL subjects: symptomatic disease requiring treatment according to the\n                  clinical judgment of the investigator;\n\n               -  Other lymphoma subjects: disease requiring treatment according to the judgment\n                  of the investigator.\n\n          4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of \u22642.\n\n          5. Subject must have measurable disease using the disease-specific response criteria for\n             NHL, CLL or T-Cell Lymphoma.\n\n          6. Age \u2265 18 years.\n\n          7. Subject has recovered from all clinically significant toxicities related to prior\n             antineoplastic therapies with the exception of alopecia and bone marrow and organ\n             functions.\n\n          8. Adequate organ system function \u22642 weeks prior to Day 1, defined as follows:\n\n               -  Absolute neutrophil count (ANC) \u22651.0 x 109/L unless related to underlying CLL or\n                  indolent NHL bone marrow involvement, and then ANC \u2265500 x 109/L permitted.\n\n               -  Platelets \u2265100 x 109/L unless related to underlying CLL or indolent NHL bone\n                  marrow involvement, and then platelets \u226575 x 109/L permitted.\n\n             Patients receiving IPI-145 plus rituximab with bone marrow involvement may enroll\n             with platelets \u226540 x 109/L.\n\n               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u22641.5 x ULN\n                  and total bilirubin \u22641.5 times the upper limit of normal (ULN) (except for\n                  subjects with Gilbert's disease)\n\n               -  Serum creatinine \u22641.5 x ULN\n\n          9. Life expectancy of \u226512 weeks.\n\n         10. Women of child-bearing potential (WCBP) must have a negative serum or urine pregnancy\n             test.\n\n         11. Ability to understand the nature of this study and give written informed consent.\n\n        Exclusion Criteria:\n\n          1. Prior allogeneic hematopoietic stem cell transplant (HSCT).\n\n          2. Prior autologous transplant or radioimmunotherapy \u22646 months prior to the first dose\n             of trial treatment.\n\n          3. Subject has a high grade lymphoma such as Burkitt's, lymphoblastic or small\n             non-cleaved cell lymphomas.  Subjects with intermediate grade lymphoma (such as\n             diffuse large B-cell lymphoma) are eligible.\n\n          4. Subjects with diffuse B-cell lymphoma must either not be eligible for autologous bone\n             marrow transplant (BMT) or relapsed after autologous BMT.\n\n          5. More than three previous cytotoxic chemotherapy regimens for subjects treated on arms\n             containing bendamustine.\n\n          6. Subjects who have had a severe allergic or anaphylactic reaction to any humanized or\n             murine monoclonal antibodies.\n\n          7. Chemotherapy, cancer immunosuppressive therapy, growth factors (except\n             erythropoietin), radiation therapy (other than whole brain irradiation [WBI]) surgery\n             or ablative therapy or investigational drugs/devices \u226428 days before first dose of\n             trial treatment.\n\n          8. Subjects receiving high doses of corticosteroids must have been tapered to a stable\n             dose at least 7 days before the first dose of trial treatment.\n\n          9. Tyrosine kinase inhibitor within 7 days prior to the first dose of trial treatment.\n\n         10. Subjects with overt leptomeningeal leukemia or central nervous system (CNS) lymphoma.\n              Subjects must be free of CNS disease for a minimum of 2 months.  Subjects with\n             symptoms of CNS disease must have a negative diagnostic lumbar puncture prior to\n             study enrollment.\n\n         11. Subjects with a history of stroke, unstable angina, myocardial infarction, or\n             ventricular arrhythmia requiring medication or mechanical control within the last 6\n             months.\n\n         12. Baseline QTcF >480 ms. Note:  This criterion does not apply to subjects with a left\n             bundle branch block.\n\n             Exclusion Criteria:\n\n         13. Subjects who have had a venous thromboembolic event requiring anticoagulation and who\n             meet any of the following criteria:\n\n               -  Have been on a stable dose of anticoagulation for <1 month.\n\n               -  Have had a Grade 2, 3 or 4 hemorrhages in the last 30 days.\n\n               -  Are experiencing continued symptoms for their venous thromboembolic event.\n\n         14. Subjects with a history of liver disease as a result of alcohol abuse, chronic\n             hepatitis, or other chronic liver disease (other than metastatic disease to the\n             liver).\n\n         15. Subjects with positive HBsAg, HBcAb or HCV are excluded.\n\n         16. Subjects with a history of tuberculosis within the preceding two years.\n\n         17. Prior surgery affecting drug absorption or any gastrointestinal dysfunction that\n             could alter drug absorption.\n\n         18. Subjects with a known hypersensitivity to bendamustine or rituximab.\n\n         19. Presence of active infection within 72 hours of treatment.  Subjects with ongoing use\n             of prophylactic antibiotics are eligible as long as there is no evidence of active\n             infection and the antibiotic is not included on the list of prohibited medications.\n\n         20. Known diagnosis of human immunodeficiency virus (HIV).\n\n         21. Concurrent administration of medications or foods that are strong or moderate\n             inhibitors or inducers of CYP3A.\n\n         22. Women who are pregnant or lactating.\n\n         23. Psychological, familial, sociological, or geographical conditions that do not permit\n             compliance with the protocol.\n\n         24. Concurrent condition that in the investigator's opinion would jeopardize compliance\n             with the protocol or would impart excessive risk associated with study participation\n             that would make it inappropriate for the subject to be enrolled.\n\n         25. Inability or unwillingness to comply with study and/or follow-up procedures outlined\n             in the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01871675", 
            "org_study_id": "SCRI HEMREF 34"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1: IPI-145 plus Rituximab", 
                    "Arm 2: IPI-145 plus Rituximab and Bendamustine", 
                    "Arm 3: IPI-145 plus Bendamustine"
                ], 
                "intervention_name": "IPI-145", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 1: IPI-145 plus Rituximab", 
                    "Arm 2: IPI-145 plus Rituximab and Bendamustine"
                ], 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug", 
                "other_name": "Rituxan"
            }, 
            {
                "arm_group_label": [
                    "Arm 2: IPI-145 plus Rituximab and Bendamustine", 
                    "Arm 3: IPI-145 plus Bendamustine"
                ], 
                "intervention_name": "Bendamustine", 
                "intervention_type": "Drug", 
                "other_name": "Treanda"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bendamustine", 
                "Rituximab", 
                "Nitrogen Mustard Compounds"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Lymphoma", 
            "Chronic Lymphocytic Leukemia", 
            "Non-Hodgkin Lymphoma", 
            "T-cell Lymphoma", 
            "Rituxan", 
            "Bendamustine", 
            "Hematologic Malignancy", 
            "Relapsed", 
            "Refractory"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "The Colorado Blood Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34232"
                    }, 
                    "name": "Florida Cancer Specialists"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "Oklahoma University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology, PLLC"
                }, 
                "investigator": {
                    "last_name": "Ian W. Flinn, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Select Subjects With Lymphoma or Chronic Lymphocytic Leukemia", 
        "other_outcome": [
            {
                "description": "To evaluate pharmacokinetics (PK) of IPI-145 and its metabolites when combined with rituximab, bendamustine/rituximab, or bendamustine by evaluating maximum concentration and area under the curve pre-dose and up to 6 hours post-dose.", 
                "measure": "PK of IPI-145 and its metabolites", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "To evaluate pharmacodynamics (PDx) of IPI-145 when combined with rituximab, bendamustine/rituximab, or bendamustine by assessing chemokines and cytokines.", 
                "measure": "PDx of IPI-145", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "description": "To develop molecular predictors of response when IPI-145 is combined with rituximab, bendamustine/rituximab, or bendamustine by assessing protein expression and potential mutations.", 
                "measure": "Molecular predictors of IPI-145", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }
        ], 
        "overall_contact": {
            "email": "asksarah@scresearch.net", 
            "last_name": "Trial Info", 
            "phone": "1-877-691-7274"
        }, 
        "overall_official": {
            "affiliation": "SCRI", 
            "last_name": "Ian Flinn, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the tolerability, initial safety profile and MTD of IPI-145 in combination with the regimens rituximab, bendamustine/rituximab, or bendamustine by assessing subjects' adverse events, vital signs, and lab values.", 
            "measure": "Tolerability and Safety", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01871675"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To obtain preliminary information on antitumor activity of IPI-145 when combined with rituximab, bendamustine/rituximab, or bendamustine as measured by objective response rate, progression free survival and overall survival data", 
            "measure": "Antitumor activity", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years"
        }, 
        "source": "SCRI Development Innovations, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Infinity Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "SCRI Development Innovations, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}